RNXT - דינמיקת הכנסות משנה לשנה ב-12 החודשים האחרונים RenovoRx, Inc.

לוגו גרפי של RenovoRx, Inc. (RNXT)

The LTM sales growth YoY metric visualizes the expansion of the RenovoRx, Inc. (RNXT) RenovoTAMP system for combating gastric cancer. Revenues are based on the sale of targeted chemotherapy equipment to clinics. However, a liquidity deficit due to early-stage testing creates financial risks. The current value of 198.40 determines the magnitude of the metric, capturing the market consensus regarding the business's operational strength.

RNXT - צמיחת מכירות משנה לשנה (TTM) RenovoRx, Inc. בטווח 11.02.2024 - 18.11.2026

פילוחי נתונים אנליטיים מרוכזים עבור RenovoRx Corporation (RNXT)

- ציטוטים נוכחיים ותחזית שווי ממוצעת:
הערכת שווי פונדמנטלית של החברה:RenovoRx Corporation (RNXT)
סחורת הדגל של RenovoRx Corp

RenovoRx, Inc. (RNXT) is scaling its business through the distribution of specialized oncology systems and the licensing of intellectual property. This process is reflected in the year-over-year (TTM) revenue growth. This metric calculates the percentage increase in total revenue over the last twelve months relative to the same period last year. It measures the pace of commercial expansion and the market adoption of technologies. This asset is categorized as a high-risk venture investment.